Sarepta Therapeutics CSO Gilmore MMSc receives $6.4M in 2018
Sarepta Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 26, 2019
Sarepta Therapeutics reported fiscal year 2018 executive compensation information on April 26, 2019.
In 2018, five executives at Sarepta Therapeutics received on average a compensation package of $3.7M, a 64% decrease compared to previous year.
Gilmore O'Neill, M.B., M.M.Sc, Chief Scientific Officer, received $6.4M in total. 73.93% of MMSc's compensation, or $4.8M, was in option awards. MMSc also received $213.4K in non-equity incentive plan, $311K in salary, $1.2M in stock awards, as well as $2.1K in other compensation.
For fiscal year 2018, the median employee pay was $329,229 at Sarepta Therapeutics. Therefore, the ratio of Gilmore O'Neill, M.B., M.M.Sc's pay to the median employee pay was 20 to one.
Sandesh Mahatme, Chief Financial Officer, received a compensation package of $4.2M, which increased by 92% compared to previous year. 79.64% of the compensation package, or $3.4M, was in option awards.
David Tyronne Howton, Jr, General Counsel, earned $3.1M in 2018, a 72% increase compared to previous year.
Alexander Cumbo, Executive Vice President, Chief Commercial Officer, received $3.1M in 2018, which increases by 34% compared to 2017.
Douglas Ingram, Chief Executive Officer, earned $1.4M in 2018, a 97% decrease compared to previous year.
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer